Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01968902 (ClinicalTrials.gov)	November 2013	21/10/2013	Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients	A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis	Muscle Spasticity;Multiple Sclerosis	Biological: incabotulinumtoxinA;Biological: Placebo	Multiple Sclerosis Center of Northeastern New York	Merz North America, Inc.	Completed	18 Years	65 Years	All	27	Phase 4	United States
2	EUCTR2007-006268-32-IT (EUCTR)	23/01/2008	23/11/2007	EFFICACY AND SAFETYOF BOTULINUM TOXIN THERAPY ON UPPER LIMB SPASTICITY IN INFLAMMATORY AND DEMIELINIZZATING DISEASE OF CENTRAL NERVOUS SYSTEM. - ND	EFFICACY AND SAFETYOF BOTULINUM TOXIN THERAPY ON UPPER LIMB SPASTICITY IN INFLAMMATORY AND DEMIELINIZZATING DISEASE OF CENTRAL NERVOUS SYSTEM. - ND	multiple sclerosis MedDRA version: 9.1;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive	Trade Name: xeomin INN or Proposed INN: xeomin	OSPEDALE S. RAFFAELE	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy